Purpose: Defining a study population and creating an analytic dataset from longitudinal healthcare databases involves many decisions. Our objective was to catalogue scientific decisions underpinning study execution that should be reported to facilitate replication and enable assessment of validity of studies conducted in large healthcare databases.
| INTRODUCTION
Modern healthcare encounter and reimbursement systems produce an abundance of electronically recorded, patient-level longitudinal data.
These data streams contain information on physician visits, hospitalizations, diagnoses made and recorded, procedures performed and billed, medications prescribed and filled, lab tests performed or results recorded, as well as many other date-stamped items. Such temporally ordered data are used to study the effectiveness and safety of medical products, healthcare policies, and medical interventions and have become a key tool for improving the quality and affordability of healthcare. 1, 2 The importance and influence of such "real world" evidence is demonstrated by commitment of governments around the world to develop infrastructure and technology to increase the capacity for use of these data in comparative effectiveness and safety research as well as health technology assessments. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] Research conducted using healthcare databases currently suffers from a lack of transparency in reporting of study details. [13] [14] [15] [16] This has led to high profile controversies over apparent discrepancies in results and reduced confidence in evidence generated from healthcare databases. However, subtle differences in scientific decisions regarding specific study parameters can have significant impacts on results and interpretationas was discovered in the controversies over 3 rd generation oral contraceptives and risk of venous thromboembolism or statins and the risk of hip fracture. 17, 18 Clarity regarding key operational decisions would have facilitated replication, assessment of validity and earlier understanding of the reasons that studies reported different findings.
The intertwined issues of transparency, reproducibility and validity cut across scientific disciplines. There has been an increasing movement towards "open science", an umbrella term that covers study registration, data sharing, public protocols and more detailed, transparent reporting. [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] To address these issues in the field of healthcare database research, a Joint Task Force between the International Society for Pharmacoepidemiology (ISPE) and the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) was convened to address transparency in process for database studies (e.g. "what did you plan to do?") and transparency in study execution (e.g. "what did you actually do?). This paper led by ISPE focuses on the latter topic, reporting of the specific steps taken during study implementation to improve reproducibility and assessment of validity.
Transparency and reproducibility in large healthcare databases is dependent on clarity regarding 1) cleaning and other pre-processing of raw source data tables, 2) operational decisions to create an analytic dataset and 3) analytic choices (Figure 1 ). This paper focuses on reporting of design and implementation decisions to define and create a temporally anchored study population from raw longitudinal source data (Figure 1 Step 2). A temporally anchored study population is identified by a sentinel eventan initial temporal anchor. Characteristics of patients, exposures and/or outcomes are evaluated during time periods defined in relation to the sentinel event.
However understanding how source data tables are cut, cleaned and pre-processed prior to implementation of a research study ( Figure   1 Step 1), how information is extracted from unstructured data (e.g. natural language processing of free text from clinical notes), and how the created dataset is analyzed (Figure 1 Step 3) are also important parts of reproducible research. These topics have been covered elsewhere, 14, [29] [30] [31] [32] [33] [34] [35] [36] however we summarize key points for those data provenance steps in the online appendix.
| Transparency
Transparency in what researchers initially intended to do protects against data dredging and cherry picking of results. It can be achieved with pre-registration and public posting of protocols before initiation of analysis. This is addressed in detail in a companion paper led by ISPOR. 37 Because the initially planned research and the design and methodology underlying reported results may differ, it is also important to have transparency regarding what researchers actually did to obtain the reported results from a healthcare database study. This can be achieved with clear reporting on the detailed operational decisions made by investigators during implementation. These decisions include how to define a study population (whom to study), and how to design and conduct an analysis (what to measure, when and how to measure it).
| Reproducibility and replicability
Reproducibility is a characteristic of a study or a finding. A reproducible study is one for which independent investigators implementing the same methods in the same data are able to obtain the same results (direct replication 38 ). In contrast, a reproducible finding is a higher order target than a reproducible study, which can be tested by conducting multiple studies that evaluate the same question and estimand (target of inference) but use different data and/or apply different methodology or operational decisions (conceptual replication 38 ) (Table 1) .
Direct replicability is a necessary, but not sufficient, component of high quality research. In other words, a fully transparent and directly replicable research study is not necessarily rigorous nor does it necessarily produce valid findings. However, the transparency that makes direct replication possible means that validity of design and operational decisions can be evaluated, questioned and improved. Higher order issues such as conceptual replication of the finding can and should be evaluated as well, however, without transparency in study implementation, it can be difficult to ascertain whether superficially similar studies address the same conceptual question.
For healthcare database research, direct replication of a study means that if independent investigators applied the same design operational choices to the same longitudinal source data, they should be able to obtain the same results (or at least a near exact reproduction).
In contrast, conceptual replication and robustness of a finding can be assessed by applying the same methods to different source data (or different years from the same source). Here, lack of replicability would not necessarily mean that one result is more "correct" than another, or refutes the results of the original. Instead, it would highlight a need for deeper inquiry to find the drivers of the differences, including differences in data definitions and quality, temporal changes or true differences in treatment effect for different populations. Conceptual replications can be further evaluated through application of different plausible methodologic and operational decisions to the same or different source data to evaluate how much the finding is influenced by the specific parameter combinations originally selected. This would encompass evaluation of how much reported findings vary with plausible alternative parameter choices, implementation in comparable data sources or after flawed design or operational decision is corrected.
However, the scientific community cannot evaluate the validity and rigor of research methods if implementation decisions necessary for replication are not transparently reporte.
The importance of achieving consistently reproducible research is recognized in many reporting guidelines (e.g. STROBE, 34 RECORD, 39 PCORI Methodology Report, 40 EnCePP 33 ) and is one impetus for developing infrastructure and tools to scale up capacity for generating evidence from large healthcare database research. 3, [41] [42] [43] [44] [45] Other guidelines, such as the ISPE Guidelines for Good Pharmacoepidemiology Practice (GPP) broadly cover many aspects of pharmacoepidemiology from protocol development, to responsibilities of research personnel and facilities, to human subject protection and adverse event reporting. 46 While these guidelines certainly increase transparency, even strict adherence to existing guidance would not provide all the information necessary for full reproducibility. In recognition of this issue, ISPE formed a joint task force with ISPOR specifically focused on improving transparency, reproducibility and validity assessment for database research, and supported a complementary effort to develop a version of the RECORD reporting guidelines with a specific focus on healthcare database pharmacepidemiology.
Any replication of database research requires an exact description of the transformations performed upon the source data and how missing data are handled. Indeed, it has been demonstrated that when researchers go beyond general guidance and provide a clear report of the temporal anchors, coding algorithms, and other decisions made to create and analyze their study population(s), independent investigators following the same technical/statistical protocol and using the same data source are able to closely replicate the study population and results. 47 1.3 | The current status of transparency and reproducibility of healthcare database studies Many research fields that rely on primary data collection have emphasized creation of repositories for sharing study data and analytic code. 48, 49 In contrast to fields that rely on primary data collection, numerous healthcare database researchers routinely make secondary use of the same large healthcare data sources. However the legal framework that enables healthcare database researchers to license or otherwise access raw data for research often prevents public sharing both of raw source data itself as well as created analytic datasets due to patient privacy and data security concerns. Access to data and code guarantees the ability to directly replicate a study. However, the current system for multi-user access to the same large healthcare data sources often prevents public sharing of that data. Furthermore, database studies require thousands of lines of code to create and analyze a temporally anchored study population from a large healthcare database. This is several orders of magnitude larger than the code required for analysis of a randomized trial or other dataset based on primary collection. Transparency requires clear reporting of the decisions and parameters used in study execution. While we encourage sharing data and code, we recognize that for many reasons, including data use agreements and intellectual property, this is often not possible. We emphasize that simply sharing code without extensive annotation to identify where key operational and design parameters are defined would obfuscate important scientific decisions. Clear natural language description of key operational and design details should be the basis for sharing the scientific thought process with the majority of informed consumers of evidence.
| Recent efforts to improve transparency and reproducibility of healthcare database studies
To generate transparent and reproducible evidence that can inform decision-making at a larger scale, many organizations have developed infrastructure to more efficiently utilize large healthcare data sources. 9, [50] [51] [52] [53] [54] [55] [56] Recently developed comprehensive software tools from such organizations use different coding languages and platforms to facilitate identification of study populations, creation of temporally anchored analytic datasets, and analysis from raw longitudinal healthcare data streams. They have in common the flexibility for investigators to turn "gears and levers" at key operational touchpoints to create analytically usable, customized study populations from raw longitudinal source data tables. However, the specific parameters that must be user specified, the flexibility of the options and the underlying programming code differ. Many but not all, reusable software tools go through extensive quality checking and validation processes to provide assurance of the fidelity of the code to intended action. Transparency in quality assurance and validation processes for software tools is TABLE 1 Reproducibility and replicability critically important to prevent exactly replicable findings that lack fidelity to intended design and operational parameters.
Even with tools available to facilitate creation and analysis of a temporally anchored study population from longitudinal healthcare databases, investigators must still take responsibility for publically reporting the details of their design and operational decisions. Due to the level of detail, these can be made available as online appendices or web links for publications and reports.
| Objective
The objective of this paper was to catalogue scientific decisions made when executing a database study that are relevant for facilitating replication and assessment of validity.
We emphasize that a fully transparent study does not imply that reported parameter choices were scientifically valid; rather, the validity of a research study cannot be evaluated without transparency regarding those choices. We also note that the purpose of this paper was not to recommend specific software or suggest that studies conducted with software platforms are better than studies based on de novo code.
| METHODS
In order to identify an initial list of key parameters that must be defined to implement a study, we reviewed 5 macro based programs and software systems designed to support healthcare database research (listed in appendix). We used this as a starting point because such programs are designed with flexible parameters to allow creation of customized study populations based on user specified scientific decisions. 54, [57] [58] [59] [60] These flexible parameters informed our catalogue of operational decisions that would have to be transparent for an independent investigator to fully understand how a study was implemented and be able to directly replicate a study.
Our review included a convenience sample of macro based programs and software systems that were publically available, developed by or otherwise accessible to members of the Task Force. Although the software systems used a variety of coding languages, from a methodologic perspective, differences in code or coding languages are irrelevant so long as study parameters are implemented as intended by the investigator.
In our review, we identified places where an investigator had to make a scientific decision between options or create study specific inputs to create an analytic dataset from raw longitudinal source data, including details of data source, inclusion/exclusion criteria, exposure definition, outcome definition, follow up (days at risk), baseline covariates, as well as reporting on analysis methods. As we reviewed each tool, we added new parameters that had not been previously encountered and synonyms for different concepts.
After the list of parameters was compiled, the co-authors, an international group of database experts, corresponded about these items and suggested additional parameters to include. In-person discussions took place following the ISPE mid-year in London (2017).
This paper was opened to comment by ISPE membership prior to publication and was endorsed by ISPE's Executive Board on July 20, 2017. The paper was also reviewed by ISPOR membership and endorsed by ISPOR leadership.
| RESULTS
Our review identified many scientific decisions necessary to operate software solutions that would facilitate direct replication of an analytic cohort from raw source data captured in a longitudinal healthcare data source ( Table 2 ). After reviewing the first two comprehensive software solutions, no parameters were added with review of additional software tools (e.g. "saturation point"). The general catalogue includes items that may not be relevant for all studies or study designs.
The group of experts agreed that the detailed catalogue of scientific decision points that would enhance transparency and reproducibility but noted that even if every parameter were reported, there was room for different interpretation of language used to describe choices.
Therefore future development of clear, shared terminology and design visualization techniques would be valuable. While sharing source data and code should be encouraged (when permissible by data use agreements and intellectual property), this would not be a sufficient substitute for transparent, natural language reporting of study parameters. Global cleaning: The data source was cleaned to exclude all individuals who had more than one gender reported. All dispensing claims that were missing day's supply or had 0 days' supply were removed from the source data tables. Project specific cleaning: When calculating duration of exposure for our study population, we ignored dispensation claims that were missing or had 0 days' supply. We used the most recently reported birth date if there was more than one birth date reported.
| Data source

A.8 Data model conversion
Format of the data, including description of decisions used to convert data to fit a Common Data Model (CDM). The period used to assess whether exposure at the end of the period represents new exposure.
New initiation was defined as the first dispensation for Drug X after at least 180 days without dispensation for Drug X, Y, and Z.
Lookback for exposure, event free period C.12 Washout for outcome
The period prior to SED or ED to assess whether an outcome is incident.
Patients were excluded if they had a stroke within 180 days prior to and including the cohort entry date. Cases of stroke were excluded if there was a recorded stroke within 180 days prior.
Lookback for outcome, event free period D. Reporting on exposure definition should include:
D.1 Type of exposure The type of exposure that is captured or measured, e.g. drug versus procedure, new use, incident, prevalent, cumulative, timevarying.
We evaluated risk of outcome Z following incident exposure to drug X or drug Y. Incident exposure was defined as beginning on the day of the first dispensation for one of these drugs after at least 180 days without dispensations for either (SED). Patients with incident exposure to both drug X and drug Y on the same SED were excluded. The exposure risk window for patients with Drug X and Drug Y began 10 days after incident exposure and continued until 14 days past the last days supply, including refills. If a patient refilled early, the date of the early refill and subsequent refills were adjusted so that the full days supply from the initial dispensation was counted before the days supply from the next dispensation was tallied. Gaps of less than or equal to 14 days in between one dispensation plus days supply and the next dispensation for the same drug were bridged (i.e. the time was counted as continuously exposed). If patients exposed to Drug X were dispensed Drug Y or vice versa, exposure was censored. NDC codes used to define incident exposure to drug X and drug Y can be found in the appendix. Drug X was defined by NDC codes listed in the appendix. Brand and generic
D.2 Exposure risk window (ERW)
The ERW is specific to an exposure and the outcome under investigation. For drug exposures, it is equivalent to the time between the minimum and maximum hypothesized induction time following ingestion of the molecule.
Drug era, risk window D.2a Induction period 1 Days on or following study entry date during which an outcome would not be counted as "exposed time" or "comparator time". A time window during which the exposure status is assessed. Exposure is defined at the end of the period. If the occurrence of exposure defines cohort entry, e.g. new initiator, then the EAW may be a point in time rather than a period. If EAW is after cohort entry, FW must begin after EAW.
We evaluated the effect of treatment intensification vs no intensification following hospitalization on disease progression. Study entry was defined by the discharge date from the hospital. The exposure assessment window started from the day after study entry and continued for 30 days. During this period, we identified whether or not treatment intensified for each patient. Intensification during this 30 day period determined exposure status during follow up. Follow up for disease progression began 31 days following study entry and continued until the firsst censoring criterion was met.
E. Reporting on follow-up time should include:
E.1 Follow-up window (FW)
The time following cohort entry during which patients are at risk to develop the outcome due to the exposure. FW is based on a biologic exposure risk window defined by minimum and maximum induction times. However, FW also accounts for censoring mechanisms.
Follow up began on the SED and continued until the earliest of discontinuation of study exposure, switching/adding comparator exposure, entry to nursing home, death, or end of study period. We included a biologically plausible induction period, therefore, follow up began 60 days after the SED and continued until the earliest of discontinuation of study exposure, switching/adding comparator exposure, entry to nursing home, death, or end of study period.
E.2 Censoring criteria
The criteria that censor follow up.
F. Reporting on outcome definition should include:
F. The time over which patient covariates are assessed.
We assessed covariates during the 180 days prior to but not including the SED.
Baseline period G.2 Comorbidity/risk score
The components and weights used in calculation of a risk score.
See appendix for example. Note that codes, temporality, diagnosis position and care setting should be specified for each component when applicable.
G.3 Healthcare utilization metrics
The counts of encounters or orders over a specified time period, sometimes stratified by care setting, or type of encounter/order.
We counted the number of generics dispensed for each patient in the CAP. We counted the number of dispensations for each patient in the CAP. We counted the number of outpatient encounters recorded in the CAP. We counted the number of days with outpatient encounters recorded in the CAP. We counted the number of inpatient hospitalizations in the CAP, if admission and discharge dates for different encounters overlapped, these were "rolled up" and counted as 1 hospitalization.
(Continues)
If the raw source data is pre-processed, with cleaning up of messy fields or missing data, before an analytic cohort is created, the decisions in this process should be described (A7). For example, if the raw data is converted to a common data model (CDM) prior to creation of an analytic cohort, the CDM version should be referenced reported as well as any changes in assumptions applied during the data transformation. 31, 32 If cleaning decisions are made on a project specific basis rather than at a global data level, these should also be reported.
| Design
In addition to stating the study design, researchers should provide a design diagram that provides a visual depiction of first/second order temporal anchors (B1, Table 3 ) and their relationship to each other.
This diagram will provide clarity about how and when patients enter the cohort, baseline characteristics are defined as well as when follow up begins and ends. Because the terminology for similar concepts varies across research groups and software systems, visual depiction of timelines can reduce the risk of misinterpretation. We provide one example of a design diagram that depicts these temporal anchors ( Figure 2 ). In this figure, the study entry date is day 0. A required period of enrollment is defined during the 183 days prior to but not including the study entry date. There is also washout for exposure and outcome in the 183 days prior to but not including the study entry date. There are two windows during which covariates are assessed, covariates 1-5 are defined in the 90 days prior to but not including the study index date whereas covariates 6-25 are defined in the 183 days prior to but not including the index date. There is an induction period following study entry so follow up for the outcome begins on day 30 and continues until a censoring mechanism is met.
| Exposure, outcome, follow up, covariates and various cohort entry criteria
A great level of detail is necessary to fully define exposure, outcome, inclusion/exclusion and covariates. As others have noted, reporting the specific codes used to define these measures is critical for transparency and reproducibility 47, 63 especially in databases where there can be substantial ambiguity in code choice.
The study entry dates (C1) will depend on how they are selected Also critical are other key investigator decisions including 1) criteria for ensuring that healthcare encounters would be captured in 
Temporal Anchors Description
Base anchors (calendar time):
Data Extraction Date -DED The date when the data were extracted from the dynamic raw transactional data stream Source Data Range -SDR The calendar time range of data used for the study. Note that the implemented study may use only a subset of the available data.
First order anchors (event time):
Study Entry Date -SED The dates when subjects enter the study.
Second order anchors (event time):
Enrollment Window -EW The time window prior to SED in which an individual was required to be contributing to the data source
Covariate Assessment Window -CW The time during which all patient covariates are assessed. Baseline covariate assessment should precede cohort entry in order to avoid adjusting for causal intermediates.
Follow-Up Window -FW The time following cohort entry during which patients are at risk to develop the outcome due to the exposure.
Exposure Assessment Window -EAW The time window during which the exposure status is assessed. Exposure is defined at the end of the period. If the occurrence of exposure defines cohort entry, e.g. new initiator, then the exposure assessment may be a point in time rather than a window. If exposure assessment is after cohort entry, follow up must begin after exposure assessment.
Event Date -ED The date of an event occurrence following cohort entry
Washout for Exposure -WE The time prior to cohort entry during which there should be no exposure (or comparator).
Washout for Outcome -WO The time prior to cohort entry during which the outcome of interest should not occur 1 Anchor dates are key dates; baseline anchors identify the available source data; first order anchor dates define entry to the analytic dataset, and second order anchors are relative to the first order anchor It is important to report on who can be included in a study.
Reporting should include specification of what type of exposure measurement is under investigation, for example prevalent versus incident exposure (D1). 64 If the latter, the criteria used to define incidence, including the washout window, should be clearly specified (C11). For example, incidence with respect to the exposure of interest only, the entire drug class, exposure and comparator, etc. When relevant, place of service used to define exposure should also be specified (e.g. inpatient versus outpatient).
Type of exposure (D1), when exposure is assessed and duration of exposure influence who is selected into the study and how long they Outcome surveillance decisions can strongly affect study results.
In defining the outcome of interest, investigators should specify whether a washout period prior to the study entry date was applied to capture incident events (C12). If a washout period was applied, it should be clear whether the washout included or excluded the study In addition, the statistical software program or platform used to create the study population and run the analysis should be detailed, including specific software version, settings, procedures or packages (I1).
The catalogue of items in Table 2 are important to report in detail in order to achieve transparent scientific decisions defining study populations and replicable creation of analytic datasets from longitudinal healthcare databases. We have highlighted in Table 3 key temporal anchors that are essential to report in the methods section of a paper, ideally accompanied with a design diagram ( Figure 2 ). Other items from These efforts have made great strides in improving capacity for transparent evidence generation from large healthcare databases, however many involve closed systems that do not influence research conducted outside of the respective networks. Currently, there is not a clear roadmap for how the field should proceed. This is reflected in policies around the world. In the US, the recently passed 21 st Century Cures Act and Prescription Drug User Fee Act (PDUFA VI) include sections on evaluating when and how to make greater use of real world evidence to support regulatory decisions. In the EU, there is exploration of adaptive pathways to bring drugs to market more quickly by using healthcare database evidence to make approval decisions 11 and active work on harmonizing policies on use of real -world evidence from databases to inform health technology assessment decisions. 12 Regardless of whether a study is conducted with software tools or de novo code, as part of a network or independently, a substantial improvement in transparency of design and implementation of healthcare database research could be achieved if specific design and operation decisions were routinely reported. We encourage researchers to prepare appendices that report in detail 1) data source provenance including data extraction date or version and years covered, 2) key temporal anchors (ideally with a design diagram), 3) detailed algorithms to define patient characteristics, inclusion or exclusion criteria, and 4) attrition table with baseline characteristics of the study population before applying methods to deal with confounding.
The ultimate measure of transparency is whether a study could be directly replicated by a qualified independent investigator based on publically reported information. While sharing data and code should be encouraged whenever data use agreements and intellectual property permit, in many cases this is not possible. Even if data and code are shared, clear, natural language description would be necessary for transparency and the ability to evaluate the validity of scientific decisions.
In many cases, attempts from an independent investigator to directly replicate a study will be hampered by data use agreements that prohibit public sharing of source data tables and differences in source data tables accessed from the same data holder at different times.
Nevertheless, understanding how closely findings can be replicated by an independent investigator when using the same data source over the same time period would be valuable and informative. Similarly, evaluation of variation in findings from attempts to conceptually replicate an original study using different source data or plausible alternative parameter choices can provide substantial insights. Our ability to understand observed differences in findings after either direct or conceptual replication relies on clarity and transparency of the scientific decisions originally implemented.
This paper provides a catalogue of specific items to report to improve reproducibility and facilitate assessment of validity of healthcare database analyses. We expect that it will grow and change over time with input from additional stakeholders. This catalogue could be used to support parallel efforts to improve transparency and reproducibility of evidence from database research. For example, we noted that the terminology used by different research groups to describe similar concepts varied. A next step could include development of shared terminology and structured reporting templates. We also had consensus within our task force that a limited number of parameters are absolutely necessary to recreate a study population, however there was disagreement on which. Empirical evaluation of the frequency and impact of lack of transparency on the catalogue of specific operational parameters on replicability of published database studies would be a valuable next step. Empirical data could inform future policies and guidelines for reporting on database studies for journals, regulators, health technology assessment bodies and other healthcare decisionmakers, where greater priority could be placed on reporting specific parameters with high demonstrated influence on replicability. It could also help stakeholders create policies that triage limited resources by focusing on database evidence where reporting is transparent enough that validity and relevance of scientific choices can be assessed. By aligning incentives of major stakeholders, the conduct and reporting of database research will change for the better. This will increase the confidence of decision-makers in real-world evidence from large healthcare databases.
